Tham khảo Nemonoxacin

  1. ↑ Guo, B; Wu, X; Zhang, Y; Shi, Y; Yu, J; Cao, G; Zhang, J (2012). “Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses”. Clinical Drug Investigation. 32 (7): 475–86. doi:10.2165/11632780-000000000-00000. PMID 22650326.
  2. ↑ “TaiGen releases Taigexyn (nemonoxacin) capsules in Taiwan”. 16 tháng 12 năm 2015.
  3. ↑ Biotechnology, TaiGen. “TaiGen Biotechnology Out-Licenses Taigexyn® (Nemonoxacin) to Productos Científicos for the Latin American Market”.
  4. ↑ “A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP - Full Text View - ClinicalTrials.gov”.
  5. ↑ “FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin”. 23 tháng 12 năm 2013.
  6. ↑ Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH (2010). “Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates”. Antimicrob. Agents Chemother. 54: 1338–1342. doi:10.1128/aac.01197-09. PMC 2825994.
  7. ↑ Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG (2009). “In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates”. Antimicrob. Agents Chemother. 53: 4915–4920. doi:10.1128/aac.00078-09. PMC 2772340.
  8. ↑ van Rensburg DJ, Perng RP, Mitha IH, Bester AJ, Kasumba J, Wu RG, Ho ML, Chang LW, Chung DT, Chang YT, King CH, Hsu MC (2010). “Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia”. Antimicrob. Agents Chemother. 54: 4098–4106. doi:10.1128/aac.00295-10. PMC 2944601.
  9. ↑ Liao, C. H.; Ko, W. C.; Lu, J. J.; Hsueh, P. R. (2012). “Characterizations of Clinical Isolates of Clostridium difficile by Toxin Genotypes and by Susceptibility to 12 Antimicrobial Agents, Including Fidaxomicin (OPT-80) and Rifaximin: A Multicenter Study in Taiwan”. Antimicrobial Agents and Chemotherapy. 56 (7): 3943–3949. doi:10.1128/AAC.00191-12. PMC 3393409. PMID 22508299.
  10. ↑ Liang, W; Chen, Y. C.; Cao, Y. R.; Liu, X. F.; Huang, J; Hu, J. L.; Zhao, M; Guo, Q. L.; Zhang, S. J. (2013). “Pharmacokinetics and Pharmacodynamics of Nemonoxacin against Streptococcus pneumoniae in an in Vitro Infection Model”. Antimicrobial Agents and Chemotherapy. 57 (7): 2942–2947. doi:10.1128/AAC.01098-12. PMC 3697386. PMID 23587953.

Tài liệu tham khảo

WikiPedia: Nemonoxacin http://www.prnewswire.com/news-releases/taigen-bio... http://chemapps.stolaf.edu/jmol/jmol.php?model=C%5... http://pubchem.ncbi.nlm.nih.gov/summary/summary.cg... //www.ncbi.nlm.nih.gov/pmc/articles/PMC2772340 //www.ncbi.nlm.nih.gov/pmc/articles/PMC2825994 //www.ncbi.nlm.nih.gov/pmc/articles/PMC2944601 //www.ncbi.nlm.nih.gov/pmc/articles/PMC3393409 //www.ncbi.nlm.nih.gov/pmc/articles/PMC3697386 //www.ncbi.nlm.nih.gov/pubmed/22508299 //www.ncbi.nlm.nih.gov/pubmed/22650326